Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Determine whether EGFR and KRAS mutations carry prognostic significance in non-small cell lung cancer (NSCLC) patients with brain metastases treated with stereotactic radiosurgery.

Methods And Materials: Ninety-four NSCLC patients with brain metastases initially treated with stereotactic radiosurgery were retrospectively reviewed. Both EGFR and KRAS mutation status were recorded in 67 patients: EGFR+/KRAS- status in 9 patients, EGFR-/KRAS+ in 15 patients, and EGFR-/KRAS- in 43 patients. Survival was determined using the Kaplan-Meier method. Cox regression was used to assess the effects of patient factors on overall survival, local control, and distant brain control - all from time of brain metastasis diagnosis.

Results: Median overall survival from time of brain metastasis diagnosis was 30.6 months for EGFR+/KRAS- patients, 9.8 months for EGFR-/KRAS+ patients, and 19.1 months for EGFR-/KRAS- patients (p=0.094). Local control at 2 years was 100% for EGFR+/KRAS- patients, 66.7% for EGFR-/KRAS+ patients, and 97.2% for EGFR-/KRAS- patients (p=0.399). Distant brain control at 12 months was achieved in 66.7% of EGFR+/KRAS- patients, 30.0% of EGFR-/KRAS+ patients, and 73.7% of EGFR-/KRAS- patients (p=0.039). On multivariate analysis, the most important predictors of mortality were baseline DS-GPA>2 (HR=0.27; p=0.001), EGFR mutation positivity (HR=0.30; p=0.054), and KRAS mutation positivity (HR=2.12; p=0.056); the most important predictors of distant brain failure were KRAS status (HR=4.44; p=0.004) and extracranial disease (HR=3.28; p=0.058); there was no statistically significant multivariate model identified for local control.

Conclusions: In NSCLC patients with brain metastases, KRAS mutations portend higher rates of distant brain failure. Our data also suggests that EGFR portends better overall survival and KRAS portends worse overall survival, though this still needs to be verified by a larger study.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746331PMC

Publication Analysis

Top Keywords

patients
17
nsclc patients
16
patients brain
16
brain metastases
16
egfr-/kras+ patients
16
egfr-/kras- patients
16
distant brain
16
egfr kras
12
kras mutations
12
egfr+/kras- patients
12

Similar Publications

In wheat allergy dependent on augmentation factors (WALDA), allergic reactions occur when wheat ingestion is combined with exercise or rarely other augmentation factors. We analyzed clinical characteristics and disease burden in recreationally active and trained individuals with WALDA diagnosed by oral challenge test. Clinical characteristics, serological data, and quality of life (QOL) questionnaires were analyzed and completed with follow-up interviews.

View Article and Find Full Text PDF

Cardiac resynchronization therapy (CRT) improves outcomes in heart failure, but prior interventions like percutaneous mitral annuloplasty may hinder lead placement. We present a 70-year-old male with ischemic cardiomyopathy and severe functional mitral regurgitation who previously received a Carillon device. Due to coronary sinus inaccessibility, left bundle branch area pacing optimized cardiac resynchronization therapy (LOT-CRT) was performed.

View Article and Find Full Text PDF

Mediastinal masses often present acutely as medical emergencies, necessitating prompt and accurate diagnosis. Imaging-guided fine needle aspiration cytology (FNAC) plays a pivotal role in rapidly identifying rare mediastinal tumours and differentiating them from other potential aetiologies, enabling timely intervention. Primary mediastinal germ cell tumours (PMGCTs) constitute approximately 15% of adult mediastinal neoplasms.

View Article and Find Full Text PDF

In an observational study, healthcare personnel often entered contact precautions rooms without contacting patients or the environment. An approach requiring gloves and gowns based on actual contacts rather than for all room entries would reduce personal protective equipment donning and doffing time, cost, and carbon footprint by more than half.

View Article and Find Full Text PDF

Medical treatment of fibroids: FIGO best practice guidance.

Int J Gynaecol Obstet

September 2025

Department of Gynecology and Obstetrics, Justus Liebig University Giessen, Giessen, Germany.

Even though uterine fibroids are a widespread condition, the range of approved medical treatment options remains limited. In fact, only a few drugs are officially approved for the therapy of fibroids. In both the USA and the European Medicines Agency region, selected gonadotropin-releasing hormone (GnRH) antagonists have been approved for this indication.

View Article and Find Full Text PDF